Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ORAGENICS INCOGEN · Entity 8495 | Chief Financial Officer | July 01, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ORAGENICS INC
Report date July 01, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2036-07-01 | Direct | 55,900 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 55,900 · Balance 55,900 F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One fifth of the options vest on the grant date and the remainder of the options subsequently vest in equal annual installments over the first, second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One fifth of the options vest on the grant date and the remainder of the options subsequently vest in equal annual installments over the first, second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 7, 2026 21:51 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (right to buy) · Derivative | 55,900 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0002144116-26-000005 · primary_doc.xml · derivative · entry 1 Spencer John · CIK 0002144116 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,900 Underlying: Common Stock · 55,900 shares Expires 2036-07-01 F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One fifth of the options vest on the grant date and the remainder of the options subsequently vest in equal annual installments over the first, second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.